ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugates (ADC) technology. The company developed its ADC technology to enable the creation of well-tolerated anticancer products. An ADC with its technology comprises an antibody that binds primarily to an antigen target found on the surface of cancer cells with one of its potent cancer-cell killing agents, or payloads, attached to the antibody using one of its engineered linkers. An ADC compound's antibody component enables it to bind to cancer cells that have its antigen on their surface and the payload agent serves to kill these cancer cells. Wholly Owned Compounds Mirvetuximab Soravtansine The company’s product candidate mirvetuximab soravtansine, or IMGN853, is a folate receptor alpha (a), or FRa,-targeting ADC that is a potential treatment for ovarian cancer and certain other FRa-positive solid tumors. This ADC comprises a FRa-binding antibody with its potent DM4 cell-killing agent attached using one of its engineered linkers. Mirvetuximab soravtansine has been granted orphan drug status for ovarian cancer by the U.S. Food and Drug Administration (FDA). It also has received this designation in the EU. IMGN529 and Coltuximab Ravtansine IMGN529 and coltuximab ravtansine are potential treatments for diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. IMGN529 includes an ImmunoGen CD37-targeting antibody that, in preclinical testing, demonstrated anticancer activity. DM1 is attached to it using one of its engineered linkers. In a dose-finding Phase 1 clinical trial, initial evidence of anticancer activity was reported with IMGN529, particularly for patients with relapsed/refractory DLBCL. In preclinical models, IMGN529 has demonstrated synergistic activity with the CD20-targeting antibody Rituxan (rituximab). Coltuximab ravtansine, previously called SAR3419, is a CD19-targeting ADC that is a potential new treatment for DLBCL. In Phase 2 clinical testing this ADC had encouraging single-agent activity in the treatment of relapsed/refractory DLBCL. IMGN779 IMGN779 is a potential new treatment for acute myeloid leukemia and myelodysplastic syndrome. It comprises an ImmunoGen CD33-targeting antibody with one of its new DNA-acting payload agents, DGN462, attached using one of its engineered linkers. The company intends to submit an Investigational New Drug (IND) application for it to the FDA. Partners The company’s partners include Amgen Inc.; Bayer HealthCare (a subgroup of Bayer AG); Biotest AG; Eli Lilly and Company, or Lilly; Novartis Institutes for BioMedical Research, Inc., or Novartis; the Roche Group; Sanofi; and Takeda Pharmaceutical Company Limited. Sanofi Collaboration Agreement: In 2003, the company entered into a collaboration agreement with Sanofi (formerly Aventis) to discover, develop and commercialize antibody-based products. The collaboration agreement provides Sanofi with worldwide development and commercialization rights to new antibody-based products directed to targets that are included in the collaboration, including the exclusive right to use its maytansinoid ADC technology in the creation of products directed to these targets. Intellectual Property As of June 30, 2015, the company’s patent portfolio had a total of 659 issued patents worldwide and 645 pending patent applications worldwide. Research and Development As of June 30, 2015, the company spent approximately $111.8 million on research and development activities. History ImmunoGen, Inc. was founded in 1981. The company was incorporated in Massachusetts in 1981.
immunogen inc (IMGN:NASDAQ GS)
830 Winter Street
Waltham, MA 02451
|Ablynx NV||€11.62 EUR||-0.295|
|Abzena PLC||71.00 GBp||0.00|
|BioInvent International AB||kr2.89 SEK||0.00|
|Kyowa Hakko Kirin Co Ltd||¥1,742 JPY||-58.00|
|MorphoSys AG||€61.60 EUR||+0.239|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact IMMUNOGEN INC, please visit www.immunogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.